<SEC-DOCUMENT>0001213900-25-041739.txt : 20250512
<SEC-HEADER>0001213900-25-041739.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512080117
ACCESSION NUMBER:		0001213900-25-041739
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250512
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		25932674

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0241694-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>





     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of May  2025</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%">99.1</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="ea024169401ex99-1_alterity.htm">Alterity Prominently Featured at International MSA Congress</A></TD></TR>
  </TABLE>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 12, 2025</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024169401ex99-1_alterity.htm
<DESCRIPTION>ALTERITY PROMINENTLY FEATURED AT INTERNATIONAL MSA CONGRESS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alterity Therapeutics Prominently Featured at
the International MSA Congress</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&ndash; ATH434 Phase
2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints &ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&ndash; MSA Atrophy
Index (MSAai) enhances MSA diagnosis and monitoring &ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&ndash; bioMUSE Study
shows higher &alpha;- synuclein concentration is associated with greater burden of orthostatic symptoms &ndash;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
&ndash; 12 May 2025:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster
presentations related to Alterity&rsquo;s clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA
Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building
hope for people affected by MSA through support services, educational resources, research funding, and community engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The MSA Congress gave us an opportunity
to share the results of our Phase 2 double-blind trial of ATH434 with prominent MSA clinicians and scientists as well as community members
affected by MSA,&rdquo; said David Stamler, M.D., Chief Executive Officer of Alterity. &ldquo;The robust efficacy of ATH434, as indicated
by reduced disease severity on the MSA activities of daily living scale along with improvement in key symptoms of MSA and preserved activity
in the outpatient setting, continue to generate enthusiasm. Our clinical progress is generating significant excitement, and we are focused
on bringing this therapy to patients as quickly as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;In addition, our colleagues at Vanderbilt
University Medical Center presented data from our bioMUSE Natural History Study that highlights the understanding of MSA we have brought
to our development program. Because of the variability in MSA presentation and progression and its similarity to Parkinson&rsquo;s disease,
it is critical to improve diagnostic and monitoring tools. Through development of a novel imaging biomarker known as the MSA Atrophy Index
(MSAai), we have a new tool to measure and track brain volume in individuals with MSA. In a separate presentation, the bioMUSE study demonstrated
that &alpha;-synuclein levels in the skin increased over the 12-month follow-up period, and that a higher concentration of &alpha;-synuclein
in skin is associated with greater burden of orthostatic symptoms, a valuable finding that confers insight into disease progression.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Presentation Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>ATH434 Slowed Disease
Progression in a Phase 2 Study in Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presenter: David Stamler, M.D., Chief Executive
Officer of Alterity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The oral and poster presentation highlighted data
from Alterity&rsquo;s ATH434-201 Phase 2 clinical trial. The clinical analysis included 71 patients who had at least one post-baseline
assessment of the key clinical endpoint, the modified UMSARS<SUP>1</SUP> I activities of daily living scale. On this endpoint, ATH434
demonstrated a clinically significant reduction in disease severity versus placebo, with a 48% relative treatment effect at the 50 mg
dose (p=0.02)<SUP>^</SUP> and a 30% relative treatment effect at the 75 mg dose (p=0.16) at 52 weeks. Additional efficacy assessments
showed improvement consistent with the UMSARS I findings: the Clinical Global Impression of Severity Scale<SUP>2</SUP> demonstrated improvement
compared to placebo at both dose levels, with difference at 50 mg achieving nominal statistical significance (p=0.0088). On the Orthostatic
Hypotension Symptom Assessment (a patient reported outcome), on average placebo patients worsened by approximately 6 points over 52 weeks
whereas both ATH434 treatment groups improved over the same period (p=0.08 at 50 mg, p=0.14 at 75 mg). Baseline differences in disease
severity likely explain different response in 50 mg and 75 mg treatment groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Increased activity in the outpatient setting was
observed at both dose levels as compared to placebo with wearable sensors, with clinically meaningful improvements in step count, bouts
of walking, total walking time, and total standing time. ATH434 was well tolerated with similar adverse event rates compared to placebo
and no serious adverse events attributed to ATH434. Regarding neuroimaging in 61 participants, ATH434 demonstrated target engagement by
stabilizing or reducing iron accumulation at both dose levels compared to placebo in MSA affected brain regions. In addition, ATH434 demonstrated
trends in reducing brain atrophy at both dose levels compared to placebo. Overall, the study results support continued advancement of
ATH434 for the treatment of MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>MSA Atrophy Index
(MSAai): A Quantitative Imaging Marker for Diagnosis and Monitoring of Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presenter: Amy Brown, M.D., M.S., Assistant Professor,
Movement Disorders Division, Department of Neurology, Vanderbilt University Medical Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This oral presentation described the MSA Atrophy
Index (MSAai) as a promising imaging biomarker that distinguishes MSA from related disorders, correlates with clinical presentation, and
tracks disease progression. Its implementation has the potential to enhance MSA diagnosis and monitoring in both clinical trials and clinical
practice. The MSAai imaging tool was developed by the team at Vanderbilt University Medical Center as part of the bioMUSE Natural History
Study. The study evaluated the utility of volumetric measures and the MSAai in distinguishing early MSA from other movement-related disorders,
correlating with clinical presentation, and tracking longitudinal changes in brain structure. The study results showed that fluid biomarkers
classified bioMUSE participants into MSA (n=10), Lewy body disorders (n=5; PD or DLB), and &alpha;-synuclein-negative (n=2) groups. At
baseline, MSA patients had significantly lower LN, brainstem, cerebellum, and MSAai values compared to HC, PD, DLB, and PAF (all p&lt;0.001).
The MSAai demonstrated strong group discrimination, correlated with UMSARS scores (&rho;=-0.46, p=0.038), and predicted clinical progression
(&rho;=0.58, p=0.022). Longitudinally, reductions in LN, brainstem, and MSAai volumes were strongly associated with UMSARS progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cutaneous Phosphorylated Alpha-Synuclein Deposition
Informs Autonomic Function in Individuals with Early-Stage Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presenter: Leah Mann, PhD, Postdoctoral Research
Fellow, Vanderbilt University Medical Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This poster presentation evaluated 17 participants
from the bioMUSE Natural History Study who met criteria for clinically probable MSA. The study compared &alpha;-synuclein deposition in
skin at baseline and 12 months later and examined associations between clinical measures and &alpha;-synuclein quantitation over the year.
The analysis described the relationship between &alpha;-synuclein and autonomic function and revealed that cutaneous &alpha;-synuclein
detection may serve as an effective diagnostic biomarker that can additionally track progression of MSA. Importantly, deposition of &alpha;-synuclein
may confer insight into symptomatology, as higher &alpha;- synuclein concentration is associated with greater burden of orthostatic symptoms.
In the analysis, 100% (17/17) of patients exhibited detection of phosphorylated &alpha;-synuclein by skin biopsy. Cutaneous &alpha;-synuclein
deposition significantly increased (<I>p </I>= 0.042) from baseline (mean = 6.59 &plusmn; 4.37) to 12-month follow-up (mean = 7.71 &plusmn;
4.22). Deposition at 12-month follow-up was positively correlated with Orthostatic Hypotension Questionnaire (OHQ) and Composite Autonomic
Symptom Score-31 (COMPASS-31) (OHQ: coefficient = 0.579, <I>p </I>= 0.015; COMPASS-31: coefficient = 0.560, <I>p </I>= 0.024).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presentations will be available on the Alterity
Therapeutics website here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ATH434</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity&rsquo;s lead candidate, ATH434, is an
oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically
to reduce &alpha;-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models.
As an iron chaperone, it has excellent potential to treat Parkinson&rsquo;s disease as well as various Parkinsonian disorders such as
Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the agent is well tolerated and achieved brain levels comparable to efficacious
levels in animal models of MSA. Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients
with MSA demonstrated robust clinical efficacy, target engagement on key biomarkers, and a favorable safety profile. A second Phase 2
open-label biomarker trial in patients with more advanced MSA is ongoing. ATH434 has been granted Fast Track Designation by the U.S. FDA,
and Orphan Drug Designation by the U.S. FDA and the European Commission for the treatment of MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ATH434-201 Phase 2 Clinical Trial </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ATH434-201 Phase 2 clinical trial is a randomized,
double-blind, placebo-controlled investigation of 12 months treatment with ATH434 in patients with MSA. The study evaluated the efficacy,
safety and pharmacokinetics of ATH434 as well as the effect of ATH434 on neuroimaging and protein biomarkers. Wearable sensors were employed
to evaluate motor activities outside of the clinic. The study enrolled 77 adults who were randomly assigned to receive ATH434 50 mg or
75 mg twice daily or matching placebo. The data showed that, compared to placebo, ATH434 produced clinically and statistically significant
improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part&nbsp;I, a functional rating scale that assesses
disability on activities of daily living affected in MSA. Additional efficacy assessments demonstrated improvement consistent with the
positive UMSARS Part I findings including trends in improved motor performance on the Parkinson&rsquo;s Plus rating scale, the Clinical
Global Impression of Severity Scale, and the Orthostatic Hypotension Symptom Assessment (a patient reported outcome). Wearable sensor
data indicated that ATH434 also led to increased activity in an outpatient setting. Biomarkers were used to evaluate potential drug effect
and target engagement relative to placebo. Both dose levels reduced iron accumulation in MSA affected brain regions with trends in preservation
of brain volume. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious adverse events attributed
to ATH434. Additional information on the Phase 2 trial can be found by ClinicalTrials.gov
Identifier: NCT05109091.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About bioMUSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Biomarkers of progression in Multiple System Atrophy
(bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved
therapy.&nbsp; The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction
of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing
disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity&rsquo;s randomized
ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE
continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement
and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently
enrolling in the Phase 2 clinical trial.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Multiple System Atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Multiple System Atrophy (MSA) is a rare, neurodegenerative
disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function
and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability.
MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that
affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes
to falls. A pathological hallmark of MSA is the accumulation of the protein &alpha;-synuclein within glia, the support cells of the central
nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while some of the
symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no
cure.<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Multiple System Atrophy | National Institute of Neurological
Disorders and Stroke (nih.gov)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company is initially focused
on developing disease modifying therapies in Parkinson&rsquo;s disease and related disorders. Alterity recently reported positive data
for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive
Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad
drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company
is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company&rsquo;s website
at www.alteritytherapeutics.com.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
Authorisation &amp; Additional information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22.55pt 0pt 0">This announcement was authorized by David Stamler, CEO
of Alterity Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 22.55pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor and Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Millie Macdonald<BR>
Head of Investor Relations and Business Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mmacdonald@alteritytherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61&nbsp;468 304 742</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61 452 510 255</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.45pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.45pt 0pt 0; text-align: justify"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;evidences&rdquo; and &ldquo;estimates,&rdquo; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.4pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.4pt 0pt 0; text-align: justify"><I>Important factors that could cause
actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on
Form 6-K, including, but not limited to the following: statements relating to the Company&rsquo;s drug development program, including, but not
limited to the initiation, progress and outcomes of clinical trials of the Company&rsquo;s drug development program, including, but not limited
to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval,
production and marketing of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to
procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&rsquo;s drug
compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent
protection for the Company&rsquo;s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent
rights and the uncertainty of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.4pt 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.4pt 0pt 0; text-align: justify"><I>Any forward-looking statement made
by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V -T# 2(  A$! Q$!_\0
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M9@J.$HT(U,7C,+0K4U+%0HPY</.A@KUHX95,)^7_ $=LJXPX6X,S/&<;X_\
MLWA]UJM;*,NSBO".*RN&&Q.*HYKF&*Q->O*&!PN-Q='$<F"E7GS5J=7,&J=3
M&VQWMM%>/_!#X\?"W]HKP+9_$3X2^*;3Q/X<NI9+2<QAK?4M)U"(*TVF:UID
MVVZTV_C1XY5BG0)<6TL-Y:27%I/#/)[!7X;B<-B<%B*^$QF'K87%8:K.AB,-
MB:52AB*%:G)QJ4JU&K&%2G4A)6E"<(R3MI9IO^D<-B</C,/1Q>$KT<5A<32A
M6P^(P]6%:A7HU(J5.K2JTY3IU*<XM.,H2::[--1****P-@HHKR'X_P#QK\%_
MLX?!'XK_ !Z^(EX++P5\(O 7B;Q]XAD\Q(YI['PWI=QJ(TZS+_*^I:M/##I>
MEP8+7.HWEK;HK/*JEI-M))MMI)+5MMI))=6VTEYL#UZBO\_W]CK_ (.J_P!K
MCQU^V!\'/"O[2NB_ C1/V:_'OQ+M?"?C5_#'@O7-)\1>#?#OBVZGT;1==3Q/
M>^,+V%[?PCJ5_I.J:S<76D,-1T2PU$?9[:XN8I(/] %65E#*0RL RLI!5E(R
M""."".01P1R*[,=E^)R^=.GB8QC*K352/++G5F[.+:22G%M*4=TVM61"<9WY
M;Z.SNK:VOIY"T5_(-_P=+?MN_M:?L>:M^QLO[,?Q\^(/P6A\=6/QE/C"W\$:
MG!IT7B*30[KX=+H\NI>9:SRRR::FIZBEKLDC15O9RZ.Q1D_IU_9:\5ZSXE_9
M3_9S\<>,=9N];\0>(/V>_A%XK\5>(-2=)+_5]9U7X<>'M7US6;^2-(XWN[^]
MGNKVZ=(XT::61E1%(435P=2EA<+BY2@X8J5:,(KFYXNC+EES77+J]N5OS&I)
MRE'6\;7[:JZL?0E%?DK_ ,$X/^"Q7[.?_!3GQU\:_ ?P,\&?%3PW>_ ZST/4
M/$&I^/\ 3?#-CI>LV?B#6-;T?39M!?0O$VNW,@DDT.XN76_M[%E@EBX,HD1/
MUJK"K2J49NG5A*G4C;FA)6DN9*2NKO>+37DRD[ZH****S **** "BOXZ/^"K
M?P:_X+M^*/\ @K#^S9XN_9?\4WLWPBMM9G'[.&M^!$U33/A!\*;-;* _$I/V
MF;.;[=9SWVL:0MRFNZCK\>H:=XS\,-!X;\"6B:NMQX=@_J&^._Q^TW]DW]EK
MQ]^T3\<\ZY:_!;X6R^-OB4GP^TX0#7-3T32K=M:@\%Z5K^KH8(]6U@R0Z!8:
MQK9DACN;6"]U&21)+ANNKA53AA90KT:\\3#F]E1DY5*,G)1C3J)I)2DY))73
MYE)6LE.:3O?1JSMK97\UJ]#Z1HKX%_X)S?\ !0[X1_\ !3#X$:K^T!\%_"_C
MWPEX3TCX@ZY\.;C3/B)9:)8ZY)K&@Z5H&L75W#%H&M:]8MI\MMXBLDA<WHF\
MZ.X22% BL_WU7/4ISI5)TJL7"I"3C.$M)1DK735WJKKJ]QA1114 %?.7[5]_
M\4M-^!GC2\^$,%S-XLBM4,IT]&EU>#0SO_MBXT>)")7OXH-N3;9O8K-KN?3P
M;^*VKPO]HS]NG0OA%X@7PGX,TJQ\7ZU8RLNO7-Q/-_9EB\,FR?3[9K66%KF]
MB*2Q3R^>(;6Y7R1%<O%="W^BO@'^T!X+^/\ X337O#DR6>L6:1)XB\-3SI)?
MZ-<R;U5P0(VNM-N7BE^Q7ZQ1K)Y<D,T<%U%- GU]'ASB'(L)E7%^,R%U\FCC
M<+B(K&0C4P]>,:M.K1ACL+&3Q%#"8Y1Y:%:O1A2KWBX<R<(8G\EK>(OA]QUF
MO%7A5DO'*PO%:RS,\NQ$\GK3P^.P=:5"IAL;4R/,ZE/ZACLTR:53FQF'P.(K
MUL'*-:-36GB*V7_R/ZY/J$VH7$US)=S:I+<GS&8DWDEVYX=B%)9VP5CVC:J!
M D1CVN?Z>/\ @GWJOQGU?]G70KGXS)<-=)?RP^!KS4A(-;O_  &FGZ:=*GU4
MR@2R[+UM2M],NILRW6D0V,P>:W:WN)N"\4?LA?!75_VQ/#?B.[\-6QL=5\"Z
M_P".M5\++&B^']1\4Z/X@TBPCO;BP">4;.\&L&\U#3EVVMY>VI::)[>]OH)O
MJ7]H/]H3X=_LT_#R^\<^.KV.-(89+?P[X:LY(4U?Q+J<<68-,TJW;B.%"8S>
MW[QFUTVV(DEWRO;VUQ^H>(_'6'X[R_AGAO(<BKXC,,=]0Q\)U</">.H8G$0K
M8:&69=&BW%^VJ4ZWURO!T<+5P]'"<M&BH5I8+\5\"O!_,?"+-N-N+>*^*L/A
M<JRQYGDOLL/BJM'*\QP>$J4,;//\Y6*MR3IK%T7EV%E&OCJ>-Q&8N>+Q$:F#
MPV,Y#]F YN?VD_N_\G3?$X''MI/@X?-Q][&.O;!SC%?S!_\ !6;5_CY>_M1>
M*[/XQB_MO#NG7&HQ?"6SB-P/#*_#Z2_F_L:\T<;1:R7NHVD4-QXAN@7NGUR*
MYM+IU^P0V]I^E_[!_P#P4A\-7/Q-^(_@CXQ0:9X+M/C'\4-=^(/AOQ)]I>/1
MM%\0>)4L;1_#6L7%P-MOIDT.FV$&EZI-*/LDZ.=3(MKI[G3OTF_;P^ 7PY^/
M?[-WQ)M?&^DP7&I>#/!7BOQEX,\101QG5O#VN:)H=UJD,ME<Y5GL=1:QAM=5
ML'D%M>VQ23]U>6UE=VNF08[%^$WB?0Q/$N00K8?-L-EV$P^,C!59X6EBL/D>
M%J9AD^(NZ-2K1Q,*F"S&FFJ_L8UX4W3E.@\9]AFU#+O&;PIE3X1XDJ4\1DF.
MS'&U\'*4L+#$XC"8O/,;2P&<X36O3IUL'6IX[*J\E/#_ %B5&K4C4=/$QP'\
MT?\ P1^US]H:Q_:P\/Z1\(H]6O/ .HR1-\:+202MX4@\#Q/*)]3U=G(M+;5;
M261O^$6F1AJ,NLRI8VQ-C>:M#<?V4U\D_L6? +X9?L[?L]> M#\ :/;Z<WB'
MPIX<\7^,O$-UY;:OXF\0ZMH=I?WVJ:S?L [06QN);?3++<MGI.GHMO;H";B:
M?\H/VMO^"[OA7X._%IO /P)\!:#\7O#/ABZ-KXS\::EK5]8:=K%W#,4O;#P/
M+IT<D<EK:A3''XEO%O[/4;@R-8:9/IT5MJ.H<7&%/.O&OC[,9<%<+\T<KPT\
M%6Q2='"U,92P6)Q5&EF6=8[$5*6#I8G%SIO"9;AYU'B)8>&'PW/B:T:M7"_4
M\$T<M\(>!<NI<6\1MSS+$1QU/#SE5Q-+!U<=0P]>6791AJ<:F*JT,/&M'$8^
MM&"HRQ52M7C3P].I1I8G^A6BOFS]E7]JKX3?M@?"?2?BO\)M8%U93E+'Q)X<
MO)(%\1>"?$:P1S7GAWQ%9PR2"&ZA619K.\B+V.K6$D&HZ?--;3 K])U^*8[
M8W*\9BLNS'"U\#CL%6J8?%X3%4I4<1AZ]*7+.G5IS2E&2=FG[T9QE"I3G4IU
M*=2I^Q8/&87,,+A\=@J]+%83%T:>(PV(HS4Z5:C5BITZD)*UU)/9J,HR4H3C
M"<)P@5_'O_P=L_MPM\._@'\*OV&O!>KF'Q5\>=6M_B7\4X;2X>.>T^%7@;4R
M/"^C7@AFC<0^,?'MJ=1B1E*RQ?#^ZMYOW%X5D_KYU75--T/3-2UK6+ZUTS2-
M'L+S5-5U*^F2VLM/TW3[>2[OKZ\N)66*"UM+6&6XN)I&5(HHW=V"J37^4/\
MM5>.OVH/^"SG_!4+XV_$W]EKX<^*?B_XB75[S4_A'X1TB'2+AO#OP0^%-[IV
M@>$=2NK?Q%+8Z):V-S$=-UK6;?4G\B[\2>*+VW,-Q)J"V\GHY#A8UL6\35<(
M8?!*-:I4J-1IQJ2;C04I2]W^(N:TM'RQ5G=)Z5I\L4MW*2C9;M=;):[::(^S
M_P#@H5_P1IE_9=_X(V?L-_M76/A1=.^,-G>7.K_M22BV":E_8W[0<MIXA^%@
MUR+'[J3X:"UT3P%<Q%U,>K^+)(N?+W5_8_\ \$&?VX!^W+_P3H^$/BCQ!JXU
M/XL?!VV3X%_%[SITFU&X\2>!-/L8-!\1WV")'E\7>"KCPYKUU=.BK/K-QK,2
M,[6LC5_)I\8OAO\ \'57[0'PN\9_!;XQ> /CGXZ^%_Q"T9] \7^#M5T/]FZ'
M3-6TLW-O>16^_3ELKJR>VN[2TNK*YL+JUN;&YMH)[6:*2)&7"_X-I_VIO&/[
M#_\ P4C\<_L5?&^VU;P-8?M!7M_\(/%'A'Q&7M)?!_[0WPVO]7'A"&_MFD>"
M#4+^Z'BGX?,( RWVI^(-$*SR6]O ]>IB\-5Q>68B-6OA\5B\'6K8VG+#5?;2
M6'J34L3"=G)J$+ITOLI4VHV;L\E/EK**3C3DE'WHV3GTM)[MJRM?5]+GW%_P
M>4C.K?L%?]>7QX'YW?PM_P *_6S]NKP9_P %$O%?_!)S]BZ]_P""=OQ$_P"%
M<>+O"'P+^%WBGXRZFOB?PYX8DOOA#IG[-0EU6QAN/$6GWT=W-_::V$\5M8>1
M?!HQ+'* I9/R3_X/*"!JW[!>2!BR^/#<D#@7?PNR>3T'>OZLOA+HNI>)?^"9
M/PR\.Z-;/>ZOK_["7@S1=*M(QF2[U+5?V?\ 3;&QMHQW>>ZGBB0=V<5P5:CH
MY7D=50IS<,1BY*%6*G3E^\6DX2LI1UNT]-$WHC16]I52>O+&]GJM';T\C_-Y
M_P"",WPK_P""JWQ3\7_'VU_X)=_%"+X;^)='\.>!9_C'+-XO\)>%3J^BWNI>
M(5\)1QMXLTO4%OGM-1@UV3-D(#;&ZD^T2D7,2G^]']IG]NGXD_\ !*S_ ()0
M_#OXW?M7);?%+]JW1/AW\.OAOJ&B3:W9W-E\0OVC-:T,IJ,FHZ[HUKIUO/X?
ML9M.USQ/K]]I%G9M=Z3I%S::8MM>7UFR_P BW_!L3^W+^RY^PY\<?VL;']JW
MXI:;\%H/B+\._!-KX8U?Q5IVLG2)-6\!>)/$4^O:#J$^EZ;?3Z;K+V^OV\VG
M6UY:PQWK6&HVL<QOTMK6Y_=+_@Y$\(W7[>/_  20^$7[4W[-@UGQU\-O GCW
MPM^T'-]DT?4;34=3^#_B/PCXG\+R^-?[%NX(M3M[+16U_2-:O_M5I'/IOAV;
M4=6OHK:UL;QX>[-J2K9UAL-6I4J>$G6HQABG3=%8A3IKGC+%)<M2FJEJ<9KF
M=-2BN91Y;12E^YDT[S2DW&]VGM\.Z]&M_F?E5\!T_P"#G7_@J'X(N/VMOA1^
MT+KWPI^&7B+4]5E^'^F6WQ!TKX%>$O$]KI5W+8W,'@+PAH>F75UJN@6.I6UU
MI4&O>,[B2WU&^L[V!]>U$VMQ,GZ6_P#!$C_@KY^V)XO_ &NO''_!+[_@I38&
MX_:"\*V_BJ'P7XXU'3=%T?Q<WB7P)9'6?$'@/QDGAV.V\/\ B6.^\+0WOB?P
MKXRTRVC>^M--E6YNM<@UG2[^U_ 7_@FY\)_^"0_QW^!'A^R_::_X*/\ [5W[
M(_QT\,PW>G>+? E[XZT[PW\++V!-2OY-)U;X:ZU)X'UC3UTVXTDV:ZCHFK:I
M;:S8ZT-02*TN=,DT^]G_ &+_ ."6?[(?_!'^V_X*E> -:_8Y_;#_ &IOVI_C
MS\(_ _C[XN:CXHU]_#-S\(4T]=$A^&5UI/B#Q/J'@;POXE\3ZQ<VGC_[1IB>
M')+[2[==-S>ZDBQ16KYX^.'C#&T:N#=-4H5/J\J.65*#I5(22I2J8Q5)4JM-
MI\LI**A4<HR26D2H./NM3O*5KIU%*Z:;=HWWOV5UKJ4_^#@K_@JI^V7^P#_P
M4E^ &F? _P"+7B+3/A'IGP?^&GQ/\7_!A&TF'PA\0;ZR^)GCQ-;TK7[B71[W
M6(K'Q3I&AZ?H&L/I]Y;W,6G*TEA):W?[^J?[$'A[_@Y0^+7[3G[+?[7?Q[\4
M_%#3?V8?B3\8/A_X@^(GPOMO''@+PSH^E_!;Q1K5K/J%Q=? I=2AO-(\+Q>&
M[GS46?29O&EIIK0WER?[3#W5?%G_  =,6MM>?\%:/V7;6\ACGL[KX'?!NVN8
M90K1303_ !G^(D<T4BMD.DD3.KJ005)!!!P?]#>&&*WABMX(TA@@BCAAAC4)
M'%%$H2..-% "HB*JJH "J  ,"N;$U*.$RS*Y4\'A95L7AJ_MJU6FJDVHSG!.
M/O)1G&4W)3LY)QBM8JPTN:<VYNT9)**=K62W2_7S/XF_^"R?_!1K]M[]GO\
MX+2_ 7]G;X,_M%>./A_\%/%D?[+K:]\/M&C\/MHNH_\ ":_$&YT;Q3YQO]%O
M+X?VS8(L%T4NU^08B\LC(^C?^#HCP7_P42N?A#KGQ#^"'Q!.@?L)^'_@OH^B
M_M-^#T\4^&]/D\2>)-9^+-MIVDE?#E]I\GB+55D;5O"$4TNDW\4(M[:831+'
M!<F?\F_^"^X8_P#!P?\ LRGD@0?L9 ?^'6O2<#KWY(K^J_\ X.!/#VL^)O\
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MM'\-Z_J?B72H)M(T+4K33[F6'5=8OY9+B:%IIHYEBD<K#%L_3BOQ3_X)O_\
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+R:32V35U;6X?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
